CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies — Stella

Recruiting

Back to Non Hodgkin Lymphoma (NHL) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin

Key details

Phase

Early testing / Safety & dosing

Sponsor

Medical College of Wisconsin

Enrollment target

~100 participants

Started

May 2020

Primary completion

February 2027

Age range

18 Years – 80 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov